Immix Biopharma (IMMX) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free IMMX Stock Alerts $2.11 +0.02 (+0.96%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | finance.yahoo.comImmix Biopharma Insiders Placed Bullish Bets Worth US$625.7kMay 17, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 10.7% in AprilImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 387,500 shares, a growth of 10.7% from the April 15th total of 349,900 shares. Based on an average daily trading volume, of 204,300 shares, the short-interest ratio is currently 1.9 days. Currently, 2.8% of the shares of the company are short sold.May 15, 2024 | insidertrades.comGabriel S. Morris Buys 4,500 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) StockMay 15, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) CFO Purchases $10,035.00 in StockImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) CFO Gabriel S. Morris acquired 4,500 shares of the firm's stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $2.23 per share, with a total value of $10,035.00. Following the completion of the transaction, the chief financial officer now directly owns 85,816 shares in the company, valued at approximately $191,369.68. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 13, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024May 10, 2024 | globenewswire.comImmix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral PresentationApril 29, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 29, 2024 | globenewswire.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 29, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Decrease in Short InterestImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 349,900 shares, a drop of 10.0% from the March 31st total of 388,800 shares. Currently, 2.5% of the company's shares are short sold. Based on an average daily volume of 278,000 shares, the days-to-cover ratio is currently 1.3 days.April 18, 2024 | finance.yahoo.comImmix Biopharma, Inc. (IMMX)April 18, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United StatesApril 18, 2024 | globenewswire.comImmix Biopharma on Track to Dose NXC-201 Patients in United StatesApril 15, 2024 | globenewswire.comImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)April 2, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023March 20, 2024 | globenewswire.comImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical TrialMarch 7, 2024 | stockhouse.comImmix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness InitiativeMarch 5, 2024 | globenewswire.comImmix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness InitiativeFebruary 24, 2024 | msn.comImmix Biopharma (IMMX) Price Target Increased by 27.27% to 14.28February 22, 2024 | finance.yahoo.comIMMX Apr 2024 7.500 callFebruary 21, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | markets.businessinsider.comImmix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | finance.yahoo.comImmix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | globenewswire.comImmix Biopharma 12 Month Review Progress UpdateFebruary 13, 2024 | finance.yahoo.comIMMX Aug 2024 2.500 callFebruary 8, 2024 | finance.yahoo.comImmix Biopharma Announces Closing of $15 Million Public Offering of Common StockFebruary 8, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL AmyloidosisFebruary 7, 2024 | markets.businessinsider.comImmix Biopharma Signs Definitive $15M Titan Partnership DealFebruary 7, 2024 | finance.yahoo.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL AmyloidosisFebruary 6, 2024 | msn.comImmix Biopharma Suspends Stock Offering Pending New ProspectusFebruary 5, 2024 | finance.yahoo.comImmix Biopharma Announces Pricing of $15 Million Public Offering of Common StockFebruary 5, 2024 | finance.yahoo.comImmix Biopharma Announces Proposed Public Offering of Common StockFebruary 5, 2024 | marketbeat.comTrading was temporarily halted for "IMMX" at 03:02 PM with a stated reason of "LULD pause." Trading set to resume at 03:02 PM. February 5, 2024 | marketbeat.comTrading was temporarily halted for "IMMX" at 03:02 PM with a stated reason of "LULD pause."January 24, 2024 | markets.businessinsider.comImmix Biopharma Reveals FDA Labeling Change Notification For CAR-T ProductsJanuary 24, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T ProductsJanuary 24, 2024 | finance.yahoo.comImmix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T ProductsJanuary 15, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Increase in Short InterestImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 212,900 shares, a growth of 52.3% from the December 15th total of 139,800 shares. Based on an average daily volume of 258,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.8% of the shares of the company are short sold.January 13, 2024 | marketbeat.comShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Expands By 52.3%Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 212,900 shares, an increase of 52.3% from the December 15th total of 139,800 shares. Based on an average trading volume of 258,000 shares, the short-interest ratio is presently 0.8 days. Approximately 2.8% of the shares of the company are short sold.January 11, 2024 | finance.yahoo.comIs Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?January 4, 2024 | finance.yahoo.comImmix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory BoardDecember 18, 2023 | finance.yahoo.comImmix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory BoardDecember 15, 2023 | finance.yahoo.comInsider Spends US$267k Buying More Shares In Immix BiopharmaDecember 11, 2023 | finance.yahoo.comImmix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023November 30, 2023 | finance.yahoo.comImmix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology SummitNovember 28, 2023 | finance.yahoo.comWhat Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'November 24, 2023 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Immix Biopharma StockNovember 22, 2023 | msn.comImmix to assess cell therapy in Phase Ib/IIa AL amyloidosis trialNovember 22, 2023 | finance.yahoo.comImmix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisNovember 21, 2023 | msn.comFDA okays US clinical testing for Immix drug NXC-201November 21, 2023 | markets.businessinsider.comImmix Biopharma Announces FDA IND Clearance For CAR-T NXC-201 Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. IMMX Media Mentions By Week IMMX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMX News Sentiment▼1.430.82▲Average Medical News Sentiment IMMX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMX Articles This Week▼21▲IMMX Articles Average Week Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Landos Biopharma News Today BioAtla News Today Conduit Pharmaceuticals News Today XBiotech News Today Pyxis Oncology News Today Renovaro News Today Ovid Therapeutics News Today Generation Bio News Today Prelude Therapeutics News Today Omeros News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe Worst is Yet to Come…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
